Actively Recruiting
Phase 1 Trial Evaluating Safety and Effects of BL-B01D1 in Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors
Led by SystImmune Inc. · Updated on 2026-09-21
540
Participants Needed
37
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying BL-B01D1, an investigational drug, in patients with metastatic or unresectable non-small cell lung cancer NSCLC and other solid tumors. This Phase 1 trial aims to evaluate the safety, tolerability, pharmacokinetics, and initial effectiveness of BL-B01D1, including determining the best dose and schedule. The study is sponsored by SystImmune Inc. and includes patients with various advanced cancers who have progressed after standard treatments. The study includes two dosing schedules Cohort A receives BL-B01D1 via intravenous infusion on Day 1 and Day 8 every 21 days, while Cohort B receives the drug on Day 1 every 21 days. The trial has three parts dose escalation, dose finding, and dose expansion. Each cohort has different dose groups to identify the maximum tolerated dose and recommended doses for future study phases. Participants will be closely monitored for adverse events, laboratory changes, physical exams, and heart function over one year. Researchers will measure drug levels in the blood and assess tumor response, disease control, and survival outcomes. Participants will have regular visits and assessments to track safety, side effects, physical activity, and overall health during the study.
CONDITIONS
Brief Title
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Research Team
T
Tara Barrineau
T
Tara Barrineau
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here